Gene · 2348
Papers3,253
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,253
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer: a retrospective cohort study. | J Cancer Res Clin Oncol | 2026 | 41896491 | PubTator, text mining | PubMed |
| CD8 PET imaging with [89Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study. | J Immunother Cancer | 2026 | 41895717 | PubTator, text mining | PubMed |
| Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial. | Nat Commun | 2026 | 41888141 | PubTator, text mining | PubMed |
| Validation of Folate Receptor-α Selectivity of 6S-5-Methyltetrahydrofolate-Based Radioconjugates: A Prerequisite for Therapeutic Application? | J Nucl Med | 2026 | 41887740 | PubTator, text mining | PubMed |
| Folate Receptor Alpha (FRα) and the Developing Brain: From Molecular Function to Neurodevelopmental Outcomes. | Mol Neurobiol | 2026 | 41882276 | PubTator, text mining | PubMed |
| Advanced imaging techniques for tumor intraoperative navigation imaging. | Npj Imaging | 2026 | 41882234 | PubTator, text mining | PubMed |
| γδ T cells at the interface of innate and adaptive immunity in cancer. | J Immunother Cancer | 2026 | 41871873 | PubTator, text mining | PubMed |
| Folate receptor alpha (FRα) expression in tubo-ovarian and endometrial tumors: a study of 923 cases. | J Pathol Clin Res | 2026 | 41870959 | PubTator, text mining | PubMed |
| Correspondence on "Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using pre-clinical and clinical models" by Ettorre et al. | Int J Gynecol Cancer | 2026 | 41833506 | PubTator, text mining | PubMed |
| Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine. | J Clin Med | 2026 | 41827159 | PubTator, text mining | PubMed |
| Rational payload selection enables high antitumoral efficacy of an anti-EGFR antibody-drug conjugate against ovarian tumors. | Neoplasia | 2026 | 41825107 | PubTator, text mining | PubMed |
| Expression characteristics of clinically relevant antibody-drug conjugate targets in gestational trophoblastic neoplasia. | Hum Pathol | 2026 | 41812828 | PubTator, text mining | PubMed |
| Fluorescence-guided surgery in colorectal cancer: current evidence, quantitative advances, and future perspectives. | Ann Coloproctol | 2026 | 41802307 | PubTator, text mining | PubMed |
| Dual Targeting of FAP-Directed Nanoparticles and FRα-Specific CAR-T Cells Induces Additive Anti-Tumor Effects in Triple-Negative Breast Cancer. | Int J Biol Sci | 2026 | 41800236 | PubTator, text mining | PubMed |
| Treatment with Mirvetuximab-Soravtansin-first clinical experience in advanced ovarian cancer in a comprehensive cancer center. | Front Oncol | 2026 | 41800034 | PubTator, text mining | PubMed |
| Neoadjuvant chemotherapy-induced immune remodeling in ovarian cancer: implications for TIL dynamics and combination immunotherapy. | Front Immunol | 2026 | 41798957 | PubTator, text mining | PubMed |
| Clinical applications of antibody-drug conjugates in advanced non-small cell lung cancer. | Front Immunol | 2026 | 41789080 | PubTator, text mining | PubMed |
| Primary Angiosarcomas of the Thyroid: New Insights Into the Genetic Background and Potentially Targetable Therapeutic Markers of an Ultrarare Disease. | Mod Pathol | 2026 | 41786211 | PubTator, text mining | PubMed |
| Utility of Targeted RNA Analysis in Neurogenetic Disorders. | Neurol Genet | 2026 | 41783521 | PubTator, text mining | PubMed |
| Human VH-antibody-based CAR T cells targeting folate receptor-alpha show enhanced persistence and reduced T-cell exhaustion against ovarian cancer. | Biomed Pharmacother | 2026 | 41763007 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2348/papers?page=6